뉴스 목록

뉴스 목록

Using artificial intelligence to detect Parkinson's disease by reading people's breathing patterns
Using artificial intelligence to detect Parkinson's disease by reading people's breathing patterns

Parkinson's disease is notoriously difficult to diagnose because it relies primarily on the onse

더 읽어보세요 2022-08-24
Targeting specific DNA of Plasmodium may be effective in treating human malaria infection
Targeting specific DNA of Plasmodium may be effective in treating human malaria infection

Targeting a parasite's DNA could be a more effective way to combat malaria, new research from th

더 읽어보세요 2022-07-28
Vijoice is the first FDA-approved PRS treatment
Vijoice is the first FDA-approved PRS treatment

2022.04.06, Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelera

더 읽어보세요 2022-07-06
Systemic lupus erythematosus (SLE) oral new drug! BMS Novel Oral TYK2 Inhibitor deucravicitinib

Bristol-Myers Squibb (BMS) recently announced positive results from the Phase 2 PAISLEY study (NCT03

더 읽어보세요 2022-06-13
Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadelumab)
Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadelumab)

Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadel

더 읽어보세요 2022-05-13
Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension trial of the novel oral TYK2 inhibitor deucravacitinib
Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension trial of the novel oral TYK2 inhibitor deucravacitinib

Recently, Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension t

더 읽어보세요 2022-05-12
AbbVie's oral JAK inhibitor Rinvoq (upatinib) approved by NMPA
AbbVie's oral JAK inhibitor Rinvoq (upatinib) approved by NMPA

AbbVie recently announced that China’s National Medical Products Administration (NMPA) has approved

더 읽어보세요 2022-03-11
Novartis' asciminib bests Pfizer's Bosulif in phase 3 leukemia trial
Novartis' asciminib bests Pfizer's Bosulif in phase 3 leukemia trial

Novartis’ asciminib hasoutperformedPfizer’s Bosulif in a phase 3 chronic myeloid leukemia (CML) stud

더 읽어보세요 2021-11-01